State of Tennessee Department of Treasury Cuts Position in Hologic, Inc. (NASDAQ:HOLX)

State of Tennessee Department of Treasury reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 40.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,564 shares of the medical equipment provider's stock after selling 35,021 shares during the quarter. State of Tennessee Department of Treasury's holdings in Hologic were worth $3,789,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Barclays PLC raised its position in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after purchasing an additional 231,578 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Hologic in the third quarter valued at about $93,000. Tidal Investments LLC raised its holdings in shares of Hologic by 60.1% during the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after buying an additional 5,764 shares during the period. Franklin Resources Inc. lifted its position in Hologic by 171.7% during the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock worth $22,714,000 after acquiring an additional 175,855 shares in the last quarter. Finally, Oddo BHF Asset Management Sas purchased a new position in Hologic in the 3rd quarter worth approximately $1,110,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Royal Bank of Canada reduced their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Evercore ISI lowered their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $58.02 on Friday. The company has a market cap of $13.02 billion, a PE ratio of 18.30, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a fifty-two week low of $55.89 and a fifty-two week high of $84.67. The firm has a 50-day simple moving average of $61.02 and a 200 day simple moving average of $70.00. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.